Home > Insider Trading > Filing (0001628280-24-046469)

Filing Details

Accession Number:: 0001628280-24-046469
Form Type:: 4
Zero Holdings:: No
Publication Time:: 2024-11-07 20:05:46
Reporting Period:: 2024-11-05

Accepted Time:: 2024-11-07 20:05:46
SEC Url:: Form 4 Filing

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1588978	Procept Biorobotics Corp	PRCT	Surgical & Medical Instruments & Apparatus (3841)	260199180

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1881616	Rohit Antal Desai	C/O Procept Biorobotics Corporation 150 Baytech Drive San Jose CA 95134		Yes	No	No	No

Reported Non-Derivative Transactions

Show Other Fields >>

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
Common Stock	Disposition	2024-11-05	660,302	$0.00	0	No	4	J	Indirect	By White Tailed Ptarmigan, LP
Common Stock	Disposition	2024-11-05	172,016	$0.00	0	No	4	J	Indirect	Mallard Fund, L.P
Common Stock	Disposition	2024-11-05	62,944	$0.00	0	No	4	J	Indirect	Kestrel Fund, L.P.
Common Stock	Disposition	2024-11-05	7,566	$95.38	256,797	No	4	S	Indirect	By The 2:22 DNA Trust
Common Stock	Disposition	2024-11-05	11,756	$96.49	245,041	No	4	S	Indirect	By The 2:22 DNA Trust
Common Stock	Disposition	2024-11-05	11,487	$97.17	233,554	No	4	S	Indirect	By The 2:22 DNA Trust
Common Stock	Disposition	2024-11-05	2,191	$98.43	231,363	No	4	S	Indirect	By The 2:22 DNA Trust
Common Stock	Disposition	2024-11-06	9,403	$95.68	221,960	No	4	S	Indirect	By The 2:22 DNA Trust
Common Stock	Disposition	2024-11-06	2,678	$96.57	219,282	No	4	S	Indirect	By The 2:22 DNA Trust
Common Stock	Disposition	2024-11-06	17,150	$97.59	202,132	No	4	S	Indirect	By The 2:22 DNA Trust
Common Stock	Disposition	2024-11-06	3,769	$98.29	198,363	No	4	S	Indirect	By The 2:22 DNA Trust
Common Stock	Disposition	2024-11-07	6,992	$94.42	191,371	No	4	S	Indirect	By The 2:22 DNA Trust
Common Stock	Disposition	2024-11-07	16,272	$95.33	175,099	No	4	S	Indirect	By The 2:22 DNA Trust
Common Stock	Disposition	2024-11-07	10,236	$96.03	164,863	No	4	S	Indirect	By The 2:22 DNA Trust
Common Stock	Disposition	2024-11-07	500	$97.54	164,363	No	4	S	Indirect	By The 2:22 DNA Trust

Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
No	4	J	Indirect	By White Tailed Ptarmigan, LP
No	4	J	Indirect	Mallard Fund, L.P
No	4	J	Indirect	Kestrel Fund, L.P.
No	4	S	Indirect	By The 2:22 DNA Trust
No	4	S	Indirect	By The 2:22 DNA Trust
No	4	S	Indirect	By The 2:22 DNA Trust
No	4	S	Indirect	By The 2:22 DNA Trust
No	4	S	Indirect	By The 2:22 DNA Trust
No	4	S	Indirect	By The 2:22 DNA Trust
No	4	S	Indirect	By The 2:22 DNA Trust
No	4	S	Indirect	By The 2:22 DNA Trust
No	4	S	Indirect	By The 2:22 DNA Trust
No	4	S	Indirect	By The 2:22 DNA Trust
No	4	S	Indirect	By The 2:22 DNA Trust
No	4	S	Indirect	By The 2:22 DNA Trust

Reported Non-Derivative Holdings

Sec. Name	Remaning Holdings	Nature of Ownership	Explanation
Common Stock	6,865	Direct

Footnotes

On November 5, 2024, White Tailed Ptarmigan, LP distributed shares on a pro rata basis, for no consideration, including 51,245 shares that were distributed in transactions exempt from Section 16 under Rule 16a-13.
CPMG, Inc. is the general partner and investment manager of each of White Tailed Ptarmigan, LP, Kestrel Fund, L.P. and Mallard Fund, L.P. (collectively, the "CPMG Funds"). Antal Desai, a member of the Issuer's board of directors and a shareholder and managing partner of CPMG, Inc., may be deemed to share voting and investment power with respect to the shares beneficially owned by the CPMG Funds. Mr. Desai disclaims beneficial ownership of the shares beneficially owned by the CPMG Funds except to the extent of any pecuniary interest therein.
On November 5, 2024, Mallard Fund, L.P. distributed all of its remaining shares on a pro rata basis, for no consideration, including 8,511 shares that were distributed in transactions exempt from Section 16 under Rule 16a-13.
Includes shares previously held indirectly through White Tailed Ptarmigan, LP, which were distributed on a pro rata basis, for no consideration, on November 5, 2024, in a transaction exempt from Section 16 under Rules 16a-9 and 16a-13.
On November 5, 2024, Kestrel Fund, L.P. distributed all of its remaining shares on a pro rata basis, for no consideration, including 3,316 shares that were distributed in transactions exempt from Section 16 under Rule 16a-13.
The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 30, 2024.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $94.64 to $95.63, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in this footnote.
Includes shares previously held indirectly through Mallard Fund, L.P., which were distributed on a pro rata basis, for no consideration, on November 5, 2024, in a transaction exempt from Section 16 under Rules 16a-9 and 16a-13.
Includes shares previously held indirectly through Kestrel Fund, L.P., which were distributed on a pro rata basis, for no consideration, on November 5, 2024, in a transaction exempt from Section 16 under Rules 16a-9 and 16a-13.
Mr. Desai and his spouse serve as co-trustees of The 2:22 DNA Trust. Mr. Desai disclaims beneficial ownership of the shares beneficially owned by The 2:22 DNA Trust except to the extent of any pecuniary interest therein.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $95.91 to $96.90, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in this footnote.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $96.91 to $97.84, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in this footnote.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $97.94 to $98.82, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in this footnote.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $95.07 to $96.04, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in this footnote.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $96.07 to $97.06, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in this footnote.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $97.07 to $98.06, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in this footnote.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $98.09 to $98.65, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in this footnote.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $93.75 to $94.74, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in this footnote.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $94.78 to $95.77, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in this footnote.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $95.78 to $96.70, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in this footnote.